Amsterdam, NL, 6 September 2007 – Elsevier announced today that it is
launching a new journal, Stem Cell Research, in September 2007. The journal
will be published 6 times a year and will focus on high quality research in
all aspects of stem cell science and applications.
The
new journal will cover
all aspects of stem cell research, including embryonic stem cells,
tissue-specific stem cells, cancer stem cells, developmental studies, stem
cell genomics and translational research. Original research, short reports and
invited reviews will be available to more than 10 million researchers via
Elsevier’s publication platform ScienceDirect.
Stem cells, which can differentiate into any type of body tissue, are seen as
key tools in scientist’s understanding of basic cell functioning and are used
to study development, cancer and organ function. Because of their ability to
divide and develop into any kind of cell, they may have therapeutic potential
in injury and disease.
Professor Andrew Elefanty, at the Monash Immunology and Stem Cell Laboratories
in Melbourne Australia, will serve as Editor-in-Chief with Associate Editors
Christine Mummery (University of Utrecht Medical Center) Markus Grompe (Oregon
Stem Cell Center), and Paul J. Simmons (University of Texas-Houston Center for
Stem Cell Research). Twenty internationally-recognized experts have agreed to
serve on the Editorial Board.
"In a few short years, stem cell research, with the promise of new cell-based
therapies for debilitating diseases, has captured the imagination of
scientists and raised the hopes of the general public like no other scientific
endeavour, “says Editor-in-Chief Andrew Elefanty. “To disseminate the results
of this continuing, exponential increase in research into stem cells, we are
proud to announce the timely launch of Stem Cell Research, dedicated to the
publication of high-quality peer-reviewed studies spanning the breadth of
embryonic and adult stem cell science. "
“It’s a field growing faster than any other in the life sciences,” says
Publisher Noelle Gracy. “It was a natural choice for a new journal launch, and
we’re very fortunate to be supported by the top researchers in the field. Our
articles in press are already receiving citations—it’s clearly a fast-moving
area.”
# # #
About Elsevier
Elsevier is a world-leading publisher of
scientific, technical and medical information products and services. Working
in partnership with the global science and health communities, Elsevier’s
7,000 employees in over 70 offices worldwide publish more than 2,000 journals
and 1,900 new books per year, in addition to offering a suite of innovative
electronic products, such as
ScienceDirect,
MD Consult,
Scopus,
bibliographic databases, and online reference works.
Elsevier is a global business
headquartered in Amsterdam, The Netherlands and has offices worldwide.
Elsevier is part of
Reed Elsevier Group
plc, a world-leading publisher and information provider. Operating in the
science and medical, legal, education and business-to-business sectors, Reed
Elsevier provides high-quality and flexible information solutions to users,
with increasing emphasis on the Internet as a means of delivery. Reed
Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock
Exchange), RUK and ENL (New York Stock Exchange).
Media contact:
Steve Watson
Publishing Editor
Elsevier
+31
20 485 3423
s.watson@elsevier.com